BACKGROUND: Glutathione S-transferase omega-1 (GSTO1) protects from oxidative stress, a risk factor for Alzheimer disease (AD), vascular dementia (VaD), and stroke. Polymorphisms in GSTO1 might influence the function of the protein and thus the risk of AD, VaD, and stroke. METHODS: The GSTO1 gene was screened for variations. The effect of the detected polymorphisms on the risk of AD, VaD, and stroke was evaluated. CSF levels of cholesterol and plasma homocysteine levels were compared according to the GSTO1 genotype. RESULTS: Two missense polymorphisms in exon 4 of GSTO1 (Ala140Asp and Glu155DeltaGlu) were detected and tested for their association with AD, VaD, and stroke. The Asp/Asp and Ala/Asp genotypes increased the risk of stroke (p = 0.003, OR = 2.1), and the Asp/Asp genotype increased the risk of VaD (p = 0.02, OR = 2.2). GSTO1 polymorphisms did not influence the risk of AD, but the Asp allele influenced the age at onset (p = 0.05). In nondemented probands CSF levels of cholesterol were increased in carriers of the Asp/Asp genotype (p = 0.004); however, in patients with manifest dementia the authors found decreased CSF levels of cholesterol in carriers of the Asp/Asp genotype (p = 0.028). Serum homocysteine levels in stroke patients were higher in carriers of at least one Asp allele (p = 0.011). CONCLUSION: The GSTO1 Asp allele may be a genetic risk factor for cerebrovascular diseases, and might influence the course of Alzheimer disease, even though effects vary in different studies.
BACKGROUND:Glutathione S-transferase omega-1 (GSTO1) protects from oxidative stress, a risk factor for Alzheimer disease (AD), vascular dementia (VaD), and stroke. Polymorphisms in GSTO1 might influence the function of the protein and thus the risk of AD, VaD, and stroke. METHODS: The GSTO1 gene was screened for variations. The effect of the detected polymorphisms on the risk of AD, VaD, and stroke was evaluated. CSF levels of cholesterol and plasma homocysteine levels were compared according to the GSTO1 genotype. RESULTS: Two missense polymorphisms in exon 4 of GSTO1 (Ala140Asp and Glu155DeltaGlu) were detected and tested for their association with AD, VaD, and stroke. The Asp/Asp and Ala/Asp genotypes increased the risk of stroke (p = 0.003, OR = 2.1), and the Asp/Asp genotype increased the risk of VaD (p = 0.02, OR = 2.2). GSTO1 polymorphisms did not influence the risk of AD, but the Asp allele influenced the age at onset (p = 0.05). In nondemented probands CSF levels of cholesterol were increased in carriers of the Asp/Asp genotype (p = 0.004); however, in patients with manifest dementia the authors found decreased CSF levels of cholesterol in carriers of the Asp/Asp genotype (p = 0.028). Serum homocysteine levels in strokepatients were higher in carriers of at least one Asp allele (p = 0.011). CONCLUSION: The GSTO1Asp allele may be a genetic risk factor for cerebrovascular diseases, and might influence the course of Alzheimer disease, even though effects vary in different studies.
Authors: Joseph H Lee; Sandra Barral; Rong Cheng; Inara Chacon; Vincent Santana; Jennifer Williamson; Rafael Lantigua; Martin Medrano; Ivonne Z Jimenez-Velazquez; Yaakov Stern; Benjamin Tycko; Ekaterina Rogaeva; Yosuke Wakutani; Toshitaka Kawarai; Peter St George-Hyslop; Richard Mayeux Journal: Neurogenetics Date: 2007-10-17 Impact factor: 2.660
Authors: Jean-Charles Lambert; Kristel Sleegers; Antonio González-Pérez; Martin Ingelsson; Gary W Beecham; Mikko Hiltunen; Onofre Combarros; Maria J Bullido; Nathalie Brouwers; Karolien Bettens; Claudine Berr; Florence Pasquier; Florence Richard; Steven T Dekosky; Didier Hannequin; Jonathan L Haines; Gloria Tognoni; Nathalie Fiévet; Jean-François Dartigues; Christophe Tzourio; Sebastiaan Engelborghs; Beatrice Arosio; Elicer Coto; Peter De Deyn; Maria Del Zompo; Ignacio Mateo; Merce Boada; Carmen Antunez; Jesus Lopez-Arrieta; Jacques Epelbaum; Brit-Maren Michaud Schjeide; Ana Frank-Garcia; Vilmentas Giedraitis; Seppo Helisalmi; Elisa Porcellini; Alberto Pilotto; Paola Forti; Raffaele Ferri; Marc Delepine; Diana Zelenika; Mark Lathrop; Elio Scarpini; Gabriele Siciliano; Vincenzo Solfrizzi; Sandro Sorbi; Gianfranco Spalletta; Giovanni Ravaglia; Fernando Valdivieso; Saila Vepsäläinen; Victoria Alvarez; Paolo Bosco; Michelangelo Mancuso; Francesco Panza; Benedetta Nacmias; Paola Bossù; Olivier Hanon; Paola Piccardi; Giorgio Annoni; David Mann; Philippe Marambaud; Davide Seripa; Daniela Galimberti; Rudolph E Tanzi; Lars Bertram; Corinne Lendon; Lars Lannfelt; Federico Licastro; Dominique Campion; Margaret A Pericak-Vance; Hilkka Soininen; Christine Van Broeckhoven; Annick Alpérovitch; Agustin Ruiz; M Ilyas Kamboh; Philippe Amouyel Journal: J Alzheimers Dis Date: 2010 Impact factor: 4.472
Authors: H Qureischie; R Heun; J Popp; F Jessen; W Maier; S Schmitz; F Hentschel; P Kelemen; H Kölsch Journal: J Neural Transm (Vienna) Date: 2009-01-28 Impact factor: 3.575
Authors: Leema Reddy Peddareddygari; Ana Virginia Dutra; Mark A Levenstien; Souvik Sen; Raji P Grewal Journal: BMC Neurol Date: 2009-07-22 Impact factor: 2.474